Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : CELSION CORP. (CLN was CELN) UP $.33 TO $.59 ON HUGE NEWS -- Ignore unavailable to you. Want to Upgrade?

To: Tech Master who wrote (510)	11/18/1999 10:01:00 AM
From: Captain James T. Kirk	Read Replies (1) \| Respond to of 518

FOR IMMEDIATE RELEASE: CELSION FEATURED ON FRONT PAGE OF INVESTOR'S BUSINESS DAILY FOR ADVANCED THERAPY TO HELP COMMON PROSTATE WOES FROM AGING -- Company has FDA Approval to Begin Expanded Study of its IDE-approved System -- Columbia, MD - November 17, 1999: Celsion Corporation (OTC BB: CELN) was featured today on the front page of Investor's Business Daily for its advanced benign prostatic hyperplasia (BPH) treatment system, which is designed to treat this common prostate condition that affects 50 percent of men over the age of 50. Earlier this year the Company successfully completed Phase I clinical studies of its BPH system, which has an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA). Celsion also received approval this year from the FDA to begin an expanded study of its BPH treatment with a revised design to shorten the treatment period. Today's article in Investor's Business Daily drew attention to the prevalence of BPH and the fact that men suffering from the condition now have access to new treatments that "dramatically impact your quality of life," as compared to common treatments that involve daily medication or surgery. In the feature on BPH, the journal also highlighted Celsion's system for its unique design to use microwave thermotherapy in a walk-in, one-hour treatment that, unlike many competitors' systems, does not require a post-therapy catheter. Celsion Corporation is a research and development company dedicated to commercializing medical treatment systems for cancer and other diseases using focused heat delivered by patented microwave technology. Clinicals and further development of the Company's treatment systems are being conducted by leading institutions such as the Columbia Hospital (a Columbia/HCA Healthcare member), Duke University, Duke University Medical Center, Harbor UCLA Medical Center, Massachusetts Institute of Technology and Montefiore Medical Center. ### Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, possible changes in cost of materials, expense items, capital expenditures, capital structure, and other financial items; introduction of new products and possible acquisitions of assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission